Efficacy of Lactococcus lactis strain plasma (LC-Plasma) in easing symptoms in patients with mild coronavirus disease 2019 (COVID-19): protocol for an exploratory, multicenter, double-blinded, randomized controlled trial (PLATEAU study)
Kazuko Yamamoto, Naoki Hosogaya, Tsuyoshi Inoue, Kenta Jounai, Ryohei Tsuji, Daisuke Fujiwara, Katsunori Yanagihara, Koichi Izumikawa, Hiroshi Mukae
doi: https://doi.org/10.1101/2022.02.13.22270913
Kazuko Yamamoto
1Department of Respiratory Medicine, Nagasaki University Hospital
2Clinical Research Center, National Organization Hospital, Nagasaki Medical Center
Naoki Hosogaya
3Clinical Research Center, Nagasaki University Hospital
Tsuyoshi Inoue
4Department of Physiology of Visceral Function and Body Fluid, Nagasaki University Graduate School of Biomedical Sciences
Kenta Jounai
5Kirin Central Research Institute, Research and Development division, Kirin Holdings Co., Ltd
Ryohei Tsuji
5Kirin Central Research Institute, Research and Development division, Kirin Holdings Co., Ltd
Daisuke Fujiwara
5Kirin Central Research Institute, Research and Development division, Kirin Holdings Co., Ltd
Katsunori Yanagihara
6Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences
Koichi Izumikawa
7Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences
Hiroshi Mukae
1Department of Respiratory Medicine, Nagasaki University Hospital
Article usage
Posted February 15, 2022.
Efficacy of Lactococcus lactis strain plasma (LC-Plasma) in easing symptoms in patients with mild coronavirus disease 2019 (COVID-19): protocol for an exploratory, multicenter, double-blinded, randomized controlled trial (PLATEAU study)
Kazuko Yamamoto, Naoki Hosogaya, Tsuyoshi Inoue, Kenta Jounai, Ryohei Tsuji, Daisuke Fujiwara, Katsunori Yanagihara, Koichi Izumikawa, Hiroshi Mukae
medRxiv 2022.02.13.22270913; doi: https://doi.org/10.1101/2022.02.13.22270913
Efficacy of Lactococcus lactis strain plasma (LC-Plasma) in easing symptoms in patients with mild coronavirus disease 2019 (COVID-19): protocol for an exploratory, multicenter, double-blinded, randomized controlled trial (PLATEAU study)
Kazuko Yamamoto, Naoki Hosogaya, Tsuyoshi Inoue, Kenta Jounai, Ryohei Tsuji, Daisuke Fujiwara, Katsunori Yanagihara, Koichi Izumikawa, Hiroshi Mukae
medRxiv 2022.02.13.22270913; doi: https://doi.org/10.1101/2022.02.13.22270913
Subject Area
Subject Areas
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2600)
- Dermatology (218)
- Emergency Medicine (391)
- Epidemiology (12135)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4031)
- Geriatric Medicine (380)
- Health Economics (670)
- Health Informatics (2605)
- Health Policy (994)
- Hematology (359)
- HIV/AIDS (832)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3797)
- Nursing (208)
- Nutrition (564)
- Oncology (1989)
- Ophthalmology (576)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (249)
- Palliative Medicine (72)
- Pathology (470)
- Pediatrics (1098)
- Primary Care Research (443)
- Public and Global Health (6470)
- Radiology and Imaging (1379)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (337)
- Surgery (438)
- Toxicology (51)
- Transplantation (185)
- Urology (165)